Electronic Prior Authorization Enables “Clinically Appropriate” Prescribing, Market Researcher Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Automating prior authorization would be useful for drug classes, such as COX-2s and proton pump inhibitors, where coverage varies widely, MediMedia says. The firm maintains that implementation would be less complex than PBMs have asserted.
You may also be interested in...
PBMs Object To Real-Time Prior Authorization As Part Of E-Prescribing
Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”
E-Prescribing Meeting By HHS Cmte. Set For May 25-27
Network providers RxHub and SureScripts are expected to testify. The National Health Statistics/Standards Subcommittee is charged with developing principles for electronic prescribing under the Medicare drug benefit.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.